{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:44:19Z","timestamp":1793054659518,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40263-025-01179-3","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T21:27:51Z","timestamp":1744147671000},"page":"621-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Foslevodopa\/Foscarbidopa: A Review in Advanced Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"39","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"1","key":"1179_CR1","first-page":"23","volume":"20","author":"A Antonini","year":"2024","unstructured":"Antonini A, D\u2019Onofrio V, Guerra A. New levodopa infusion systems for advanced Parkinson\u2019s disease. touchREVIEWS Neurol. 2024;20(1):23\u20136.","journal-title":"touchREVIEWS Neurol."},{"issue":"10","key":"1179_CR2","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1002\/mdc3.14161","volume":"11","author":"M Aubignat","year":"2024","unstructured":"Aubignat M, Tir M. Continuous subcutaneous foslevodopa-foscarbidopa in Parkinson\u2019s disease: a mini-review of current scope and future outlook. Mov Disord Clin Pract. 2024;11(10):1188\u201394.","journal-title":"Mov Disord Clin Pract."},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1007\/s10072-023-07278-7","volume":"45","author":"I Ullah","year":"2024","unstructured":"Ullah I, Wang X, Li H. Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms. Neurol Sci. 2024;45:2979\u201395.","journal-title":"Neurol Sci"},{"key":"1179_CR4","unstructured":"AbbVie Inc. VYALEV\u2122 (foscarbidopa and foslevodopa) injection, for subcutaneous use: US prescribing information. 2024. https:\/\/www.rxabbvie.com\/pdf\/vyalev_pi.pdf. Accessed 12 Mar 2025."},{"key":"1179_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100239","author":"VSC Fung","year":"2024","unstructured":"Fung VSC, Aldred J, Arroyo MP, et al. Continuous subcutaneous foslevodopa\/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson\u2019s disease: considerations for initiation and maintenance. Clin Park Relat Disord. 2024. https:\/\/doi.org\/10.1016\/j.prdoa.2024.100239.","journal-title":"Clin Park Relat Disord."},{"issue":"11","key":"1179_CR6","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","volume":"131","author":"N Schroter","year":"2024","unstructured":"Schroter N, Sajonz BEA, Jost WH, et al. Advanced therapies in Parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm. 2024;131(11):1285\u201393.","journal-title":"J Neural Transm"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1007\/s00702-024-02782-2","volume":"131","author":"O Phokaewvarangkul","year":"2024","unstructured":"Phokaewvarangkul O, Auffret M, Groppa S, et al. What was first and what is next in selecting device-aided therapy in Parkinson\u2019s disease? Balancing evidence and experience. J Neural Transm. 2024;131:1307\u201320.","journal-title":"J Neural Transm"},{"key":"1179_CR8","first-page":"63","volume":"7","author":"K Poplawska-Domaszewicz","year":"2024","unstructured":"Poplawska-Domaszewicz K, Chaudhuri KR. Subcutaneous foslevodopa\/foscarbidopa: a novel 24h delivery option for levodopa. Int Rev Mov Dis. 2024;7:63\u201379.","journal-title":"Int Rev Mov Dis."},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40120-024-00635-4","volume":"13","author":"K Poplawska-Domaszewicz","year":"2024","unstructured":"Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, et al. Subcutaneous levodopa: a new engine for the vintage molecule. Neurol Ther. 2024;13:1055\u201368.","journal-title":"Neurol Ther."},{"key":"1179_CR10","unstructured":"AbbVie Ltd. Produodopa (foslevodopa\/foscarbidopa) 240 mg\/ml + 12 mg\/ml solution for infusion: summary of product characteristics. 2024. https:\/\/www.medicines.org.uk\/emc\/product\/15213\/smpc#about-medicine. Accessed 12 Mar 2025."},{"key":"1179_CR11","unstructured":"AbbVie Corporation. VYALEV\u2122 foslevodopa\/foscarbidopa solution: Canadian product monograph including patient medication information. 2023. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=102649. Accessed 12 Mar 2025."},{"key":"1179_CR12","unstructured":"Medthority. Vyalev a continuous subcutaneous infusion for Parkinson's disease is now launched in Japan [media release]. 28 Jul 2023. https:\/\/www.medthority.com\/news\/2023\/7\/vyalev-a-continuous-subcutaneousinfusion-for-parkinsons-disease-is-now-launched-in-japan.-abbvie."},{"issue":"1","key":"1179_CR13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/ana.26073","volume":"90","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Voight EA, Moussa EM, et al. Foslevodopa\/foscarbidopa: a new subcutaneous treatment for Parkinson\u2019s disease. Ann Neurol. 2021;90(1):52\u201361.","journal-title":"Ann Neurol"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2022.03.012","volume":"97","author":"M Rosebraugh","year":"2022","unstructured":"Rosebraugh M, Stodtmann S, Liu W, et al. Foslevodopa\/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism Relat Disord. 2022;97:68\u201372.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1179_CR15","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3233\/JPD-212813","volume":"11","author":"M Rosebraugh","year":"2021","unstructured":"Rosebraugh M, Liu W, Neenan M, et al. Foslevodopa\/foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis. 2021;11(4):1695\u2013702.","journal-title":"J Parkinsons Dis"},{"issue":"S1","key":"1179_CR16","first-page":"S27","volume":"38","author":"Y Han","year":"2023","unstructured":"Han Y, Kalluri H, Jeong A, et al. Pharmacokinetics, safety and tolerability of foslevodopa\/foscarbidopa following continuous subcutaneous infusion to arm, thigh and flank compared to abdomen in Parkinson\u2019s disease patients [abstract no. 62]. Mov Disord. 2023;38(S1):S27.","journal-title":"Mov Disord"},{"issue":"2","key":"1179_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/prp2.1190","volume":"12","author":"JP Savaryn","year":"2024","unstructured":"Savaryn JP, Smith RL, Rosebraugh M, et al. Metabolite profiling of foslevodopa\/foscarbidopa in plasma of healthy human participants by LC-HRMS indicates no major differences compared to administration of levodopa\/carbidopa intestinal gel. Pharmacol Res Perspect. 2024;12(2):1\u201311.","journal-title":"Pharmacol Res Perspect"},{"issue":"4","key":"1179_CR18","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1002\/cpdd.1201","volume":"12","author":"M Rosebraugh","year":"2023","unstructured":"Rosebraugh M, Neenan M, Facheris M. Comparability of foslevodopa\/foscarbidopa pharmacokinetics in healthy Asian and white participants. Clin Pharmacol Drug Dev. 2023;12(4):407\u201315.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"12","key":"1179_CR19","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, et al. Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol. 2022;21(12):1099\u2013109.","journal-title":"Lancet Neurol"},{"key":"1179_CR20","doi-asserted-by":"crossref","unstructured":"Kern D, Hauser R, Kimber T, et al. Improvement of \u201con\u201d and \u201coff\u201d times in patients with advanced Parkinson\u2019s disease treated with foslevodopa\/foscarbidopa: subgroup analyses from a phase 3 randomized study [abstract no. S30.007]. Neurology. 2024;102(17_Suppl_1).","DOI":"10.1212\/WNL.0000000000204663"},{"key":"1179_CR21","unstructured":"Soileau M, Bronstein J, Harmer L, et al. Efficacy and safety of foslevodopa\/foscarbidopa in people with Parkinson\u2019s disease with and without care partner support [abstract no. 687 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024."},{"issue":"S1","key":"1179_CR22","first-page":"S7","volume":"38","author":"J Aldred","year":"2023","unstructured":"Aldred J, Henriksen T, Bouchard M, et al. Efficacy and safety of foslevodopa\/foscarbidopa continuous subcutaneous infusion administered as monotherapy in patients with Parkinson\u2019s disease [abstract no. 19]. Mov Disord. 2023;38(S1):S7-8.","journal-title":"Mov Disord"},{"issue":"S2","key":"1179_CR23","first-page":"S346","volume":"37","author":"R Pahwa","year":"2022","unstructured":"Pahwa R, Soileau M, Standaert D, et al. Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa\/foscarbidopa [abstract no. 754]. Mov Disord. 2022;37(S2):S346.","journal-title":"Mov Disord"},{"issue":"S2","key":"1179_CR24","first-page":"S354","volume":"37","author":"M Soileau","year":"2022","unstructured":"Soileau M, Aldred J, Antonini A, et al. Impact of foslevodopa\/foscarbidopa on key clinical and patient reported outcomes in patients with aPD: responder analysis of two phase 3 clinical trials [abstract no. 776 plus poster]. Mov Disord. 2022;37(S2):S354\u20135.","journal-title":"Mov Disord"},{"issue":"S1","key":"1179_CR25","first-page":"312","volume":"30","author":"P Odin","year":"2023","unstructured":"Odin P, Kimura T, Santos-Garcia D, et al. Effect of continuous subcutaneous foslevodopa\/foscarbidopa treatment on falls, posture and freezing of gait [abstract no. EPR-281]. Eur J Neurol. 2023;30(S1):312.","journal-title":"Eur J Neurol"},{"key":"1179_CR26","doi-asserted-by":"crossref","unstructured":"Malaty I, Vaou E, Hauser R, et al. Correlation between sleep and quality of life in people with Parkinson\u2019s disease treated with continuous subcutaneous infusion of foslevodopa\/foscarbidopa [abstract no. 657 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.","DOI":"10.1016\/j.parkreldis.2025.107599"},{"issue":"S1","key":"1179_CR27","first-page":"S18","volume":"38","author":"K Chaudhuri","year":"2023","unstructured":"Chaudhuri K, Bouchard M, Freire-Alvarez E, et al. Improvement of nocturia symptoms and associated quality of life in patients with Parkinson\u2019s disease treated with foslevodopa\/foscarbidopa: results from 2 phase 3 trials [abstract no. 39]. Mov Disord. 2023;38(S1):S18.","journal-title":"Mov Disord"},{"key":"1179_CR28","unstructured":"Hauser R, Fung V, Kimber T, et al. Long-term safety and efficacy of foslevodopa\/foscarbidopa in patients with advanced Parkinson\u2019s disease: results from an ongoing phase 3 open\u2011label extension with up to 1 year follow-up [abstract no. 693-098 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024."},{"issue":"6","key":"1179_CR29","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, et al. Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Ther. 2023;12(6):1937\u201358.","journal-title":"Neurol Ther."},{"key":"1179_CR30","unstructured":"Bergquist F, Aldred J, Carroll C, et al. Long-term safety and efficacy for motor fluctuations and quality of life with foslevodopa\/foscarbidopa in patients with advanced Parkinson\u2019s disease:\ninterim results from an ongoing open label extension [abstract no. 705]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024."},{"issue":"7","key":"1179_CR31","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/mdc3.14018","volume":"11","author":"KR Chaudhuri","year":"2024","unstructured":"Chaudhuri KR, Facheris MF, Bergmans B, et al. Improved sleep correlates with improved quality of life and motor symptoms with foslevodopa\/foscarbidopa. Mov Disord Clin Pract. 2024;11(7):861\u20136.","journal-title":"Mov Disord Clin Pract."},{"issue":"S1","key":"1179_CR32","first-page":"169","volume":"30","author":"T Henriksen","year":"2023","unstructured":"Henriksen T, Mart\u00ednez-Castrillo J, Huisman M, et al. Efficacy and safety of foslevodopa\/foscarbidopa subcutaneous infusion in patients with prior deep brain stimulation [abstract no. EPR-074]. Eur J Neurol. 2023;30(S1):169\u201370.","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"1179_CR33","first-page":"210","volume":"31","author":"M Blaabjerg","year":"2024","unstructured":"Blaabjerg M, Liang T, Peckham E, et al. Improvement of troublesome dyskinesia in people with Parkinson\u2019s disease treated with foslevodopa\/foscarbidopa [abstract no. EPO-361]. Eur J Neurol. 2024;31(Suppl 1):210\u20131.","journal-title":"Eur J Neurol"},{"key":"1179_CR34","doi-asserted-by":"crossref","unstructured":"Aldred J, Henriksen T, Bouchard M, et al. Treatment patterns with long-term foslevodopa\/foscarbidopa use in Parkinson\u2019s disease [abstract no. 710 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024.","DOI":"10.1016\/j.parkreldis.2025.107598"},{"issue":"S1","key":"1179_CR35","first-page":"S32","volume":"38","author":"D Kern","year":"2023","unstructured":"Kern D, Isaacson S, Dhanani S, et al. Safety of foslevodopa\/foscarbidopa during optimization and maintenance treatment: post hoc analysis of a phase 3, single-arm trial [abstract no. 74]. Mov Disord. 2023;38(S1):S32.","journal-title":"Mov Disord"},{"issue":"S1","key":"1179_CR36","first-page":"S43","volume":"38","author":"P Odin","year":"2023","unstructured":"Odin P, Kimber T, Bergmans B, et al. Integrated analysis of phase 3 trials of foslevodopa\/foscarbidopa demonstrated that majority of reported infusion site AEs including infections were non serious, mild to moderate in severity and did not result in treatment discontinuation [abstract no. 102]. Mov Disord. 2023;38(S1):S43\u20134.","journal-title":"Mov Disord"},{"issue":"S1","key":"1179_CR37","first-page":"S49","volume":"38","author":"L Schlachter","year":"2023","unstructured":"Schlachter L, Stodtmann S, Talapala S, et al. Foslevodopa\/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson\u2019s disease [abstract no. 118]. Mov Disord. 2023;38(S1):S49.","journal-title":"Mov Disord"},{"issue":"8","key":"1179_CR38","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/mds.27372","volume":"33","author":"SH Fox","year":"2018","unstructured":"Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson\u2019s disease. Mov Disord. 2018;33(8):1248\u201366.","journal-title":"Mov Disord"},{"issue":"3","key":"1179_CR39","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/mdc3.13962","volume":"11","author":"D Brinker","year":"2024","unstructured":"Brinker D, Smilowska K, Paschen S, et al. How to use the new European Academy of Neurology\/Movement Disorder Society European section guideline for invasive therapies in Parkinson\u2019s disease. Mov Disord Clin Pract. 2024;11(3):209\u201319.","journal-title":"Mov Disord Clin Pract."},{"issue":"7","key":"1179_CR40","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1002\/mds.29066","volume":"37","author":"G Deuschl","year":"2022","unstructured":"Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology\/Movement Disorder Society\u2014European section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies. Mov Disord. 2022;37(7):1360\u201374.","journal-title":"Mov Disord"},{"key":"1179_CR41","unstructured":"National Institute for Health and Care Excellence. Foslevodopa\u2013foscarbidopa for treating advanced Parkinson\u2019s with motor symptoms: technology appraisal guidance TA934. 2023. https:\/\/www.nice.org.uk\/guidance\/ta934\/chapter\/3-Committee-discussion. Accessed 12 Mar 2025."},{"key":"1179_CR42","unstructured":"Standaert D, Fasano A, Ory-Magne F, et al. Comparative-effectiveness of foscarbidopa\/foslevodopa (LDp\/CDp) versus oral therapies in advanced Parkinson\u2019s disease: a propensity matched study [abstract no. 824 plus poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2024."},{"issue":"Suppl 1","key":"1179_CR43","first-page":"S117","volume":"25","author":"M Menza","year":"2010","unstructured":"Menza M, Dobkin RD, Marin H, et al. Sleep disturbances in Parkinson\u2019s disease. Mov Disord. 2010;25(Suppl 1):S117\u201322.","journal-title":"Mov Disord"},{"issue":"6","key":"1179_CR44","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1177\/0891988720964250","volume":"34","author":"D Santos-Garcia","year":"2021","unstructured":"Santos-Garcia D, Castro ES, de Deus FT, et al. Sleep problems are related to a worse quality of life and a greater non-motor symptoms burden in Parkinson\u2019s disease. J Geriatr Psychiatry Neurol. 2021;34(6):642\u201358.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1179_CR45","unstructured":"Antonini A, Bergmans B, Kern DS, et al. Improvement in motor symptoms and quality of life in patients with an earlier stage of advanced Parkinson's disease treated with foslevodopa\/foscarbidopa subcutaneous 24-hour infusion [poster]. In: International Congress of Parkinson's Disease and Movement Disorders. 2023."},{"key":"1179_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107185","author":"P Mendes-Bastos","year":"2024","unstructured":"Mendes-Bastos P, Simoes RM. Algorithm for managing infusion site adverse events caused by subcutaneous foslevodopa\/foscarbidopa and other device-aided therapies for advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2024. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107185.","journal-title":"Parkinsonism Relat Disord"},{"key":"1179_CR47","doi-asserted-by":"crossref","unstructured":"Soileau M, Jason A, Zach B, et al. Living with continuous subcutaneous infusion of foslevodopa\/foscarbidopa for symptom management in advanced Parkinson's disease: a patient experience study [abstract no. P9.006]. Neurology. 2024;102(17_Suppl_1).","DOI":"10.1212\/WNL.0000000000205745"},{"key":"1179_CR48","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334521","author":"R Rajalingam","year":"2024","unstructured":"Rajalingam R, Sorrento G, Fasano A. Risk of fall with device-based advanced treatments in Parkinson\u2019s disease: a systematic review and network meta-analysis. J Neurol Neurosurg Psychiatry. 2024. https:\/\/doi.org\/10.1136\/jnnp-2024-334521.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl","key":"1179_CR49","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/j.parkreldis.2007.06.003","volume":"13","author":"LJ Findley","year":"2007","unstructured":"Findley LJ. The economic impact of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13(Suppl):S8\u201312.","journal-title":"Parkinsonism Relat Disord"},{"key":"1179_CR50","unstructured":"Canadian Agency for Drugs and Technologies in Health. Foslevodopa-foscarbidopa (Vyalev): CADTH reimbursement recommendation: indication: for the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson\u2019s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper-\/dyskinesia despite optimized treatment with available combinations of Parkinson\u2019s medicinal products. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK595155\/. Accessed 3 Mar 2025."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01179-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01179-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:30:41Z","timestamp":1746621041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01179-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01179-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"11 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hannah A. Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}